Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or multi-gated acquisition (MUGA) scan within 4 weeks of randomization
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= institutional lower limit of normal by multi gated acquisition scan (MUGA)/radionuclide ventriculogram (RVG) or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [D] echocardiogram is preferred; however, multi gated acquisition [MUGA] scan may be substituted based on institutional preferences;) the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal
Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) within 28 days prior to registration
Patients must have an echocardiogram (ECHO) or a nuclear study (multi-gated acquisition scan [MUGA] or first pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN); if the LLN is not defined at a site, the LVEF must be > 50% for the patient to be eligible
Cardiopulmonary dysfunction, including inadequate left ventricular ejection function at baseline, less than 50% by either echocardiogram or multiple-gated acquisition scan
Left ventricular ejection fraction (LVEF) determined by echocardiogram or multi-gated acquisition scan ? 50%
Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition Scan (MUGA).
Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 28 days prior to study registration (i.e., if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
Left ventricular ejection fraction (LVEF) of 50% or greater, as measured by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan, within 28 days before the first dose of TAK-580
Left ventricular ejection fraction (LVEF) < 45% as determined by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO).
Participant has a left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO);
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>=) 53 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans
Patients must have normal left ventricular systolic function, as demonstrated by a transthoracic echocardiogram or multi-gated acquisition scan (MUGA) scan showing a normal left ventricular ejection fraction
Cardiac: Left ventricular ejection fraction (LVEF) at rest ? 40%. For patients aged < 13 years, shortening fraction (SF) ? 26% by echocardiogram or Multi Gated Acquisition Scan (MUGA) may be substituted for LVEF.
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Normal cardiac function, as determined by left ventricular ejection fraction (LVEF) >= institutional lower limit of normal on echocardiogram or multi-gated acquisition scan (MUGA) within 1 month of registration
Left ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (multi gated acquisition scan)
Screening calculated LVEF of ?50% by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan
Baseline multi-gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%.
Left ventricular ejection fraction (LVEF) above institutional lower limit of normal (by echocardiogram or multi-gated acquisition [MUGA] scan within 90 days of registration)
Left ventricular ejection fraction determined by echocardiogram or multiple-gated acquisition scan (MUGA) (cardiac scan) must be 50% or higher
Left ventricular ejection fraction (LVEF) > 40% or LV shortening fraction > 26% by cardiac echocardiogram or by multi-gated acquisition (MUGA) scan
Patients with New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 40% by echocardiogram or multi-gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy
Left ventricular ejection fraction (LVEF) assessment by 2-dimensional (D) echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to registration must be >= 50%
Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Symptomatic congestive heart failure (New York Heart Association III-IV) or documented cardiomyopathy with left ventricular ejection fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening. MUGA/ ECHO to be performed within 28 days prior to registration.
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi-gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >/= 50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) within 5 absolute percentage points of institutional standard of normal (50-70%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (ie, if the institutional normal is 50%, subject’s LVEF may be as low as 45% to be eligible for the study)
Left ventricular ejection fraction (LVEF) assessment (i.e., 2 dimensional [2-D] echocardiogram or multi-gated acquisition [MUGA] scan) performed within 12 weeks prior to study registration indicates an LVEF >= 50% regardless of the cardiac imaging facility’s lower limit of normal
Patients must have a shortening fraction >= 27% or left ventricular ejection fraction >= 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA)
Left ventricular ejection fraction (LVEF) >= 45% by multi-gated acquisition scan (MUGA) or rest echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) of the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
Left ventricular ejection fraction >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 6 months of study entry
Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) >= 35% as assessed by echocardiogram (ECHO) or multiple uptake gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) for left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction >= 40% as confirmed by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
Baseline multi-gated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of neoadjuvant chemotherapy
Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
Baseline multi-gated acquisition (MUGA) scan or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% at least 6 weeks prior to initiation of NACT
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or magnetic resonance imaging (MRI) >= 40%
Patients must have normal cardiac function, as evidenced by a left ventricular ejection fraction (LVEF) within institutional normal limits; echocardiogram may be used if multi gated acquisition (MUGA) scan is not available, but the same test must be used throughout the study to evaluate LVEF
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (Echo) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must be greater than or equal to 50% regardless of the facility's lower limit of normal (LLN).
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricle ejection fraction (LVEF) >= 40% confirmed by echocardiogram (ECHO)/multi gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) >= 40%; 2-dimension (D) transthoracic echocardiogram (ECHO) is the preferred method of evaluation; multi gated acquisition scan (MUGA) is acceptable if ECHO is not available
Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Left ventricular ejection fraction (LVEF) =< 50% as documented by multi gated acquisition scan (MUGA) or echocardiogram performed within 28 days prior to the first study treatment
Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of 45% or greater, by multiple gated acquisition (MUGA) or echocardiogram; no ongoing cardiac issues such as uncontrolled arrhythmias or unstable angina or congestive heart failure
Left ventricular ejection fraction (LVEF) > lower limit of normal (LLN) on multi gated acquisition scan (MUGA)
The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by echocardiogram (ECHO) or by gated cardiac blood flow scan (multi gated acquisition scan [MUGA]) left ventricular ejection fraction [LVEF] > 45%)
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition scan (MUGA)/echocardiogram (ECHO)
Left ventricular ejection fraction ? 50% by echocardiogram or multiple gated acquisition scan.
Cardiac ejection fraction (LVEF) by multiple gated acquisition scan (MUGA) less than the institutional lower limit of normal.
Patients must have a baseline left ventricular ejection fraction (LVEF) measured by multi-gated acquisition scan (MUGA) equal to or greater than the lower limit of normal for the radiology facility and if there are two consecutive MUGAS performed while on trastuzumab from the same radiology facility, there cannot be a decrease in LVEF of > 15% from the original MUGA scan
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 3 weeks prior to starting study therapy
Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [ECHO])
Left ventricular ejection fraction (LVEF) < 40% as measured by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) documented within four weeks prior to first dose of study drug; adequate cardiac reserve ejection fraction (EF) >= 50%
Left ventricular ejection fraction (LVEF) >= 0.4 by multi gated acquisition scan (MUGA) or echocardiogram
Left ventricular ejection fraction (LVEF) =< 55% as determined by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days prior to randomization; (LVEF assessment performed by 2-dimensional [2-D] echocardiogram is preferred; however, multi gated acquisition scan [MUGA] scan may be substituted based on institutional preferences); the LVEF must be >= 50% regardless of the cardiac imaging facility's lower limit of normal; note: since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments, it is critical that this baseline study be an accurate assessment; if the baseline LVEF is > 65%, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and repeat the test if the accuracy is uncertain
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) greater than or equal to institutional/laboratory lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Cardiac function: left ventricular ejection fraction >= 40% by multi gated acquisition scan (MUGA) or cardiac magnetic resonance imaging (MRI), or fractional shortening >= 28% by echocardiogram (ECHO)or left ventricular ejection fraction >= 50% by ECHO
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (ILLN) (by echocardiogram [ECHO] or multi gated acquisition scan [MUGA])
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by cardiac echocardiogram (echo) or multi gated acquisition (MUGA) scan within 56 days prior to step 2 registration
Left ventricular ejection fraction (LVEF) that is at or above the lower institutional limits of normal, as assessed by multiple gated acquisition (MUGA) scan or echocardiogram within the 6 weeks prior to registration
Left ventricular ejection fraction (LVEF) >= 45%, preferably by 2-dimensional (D) echocardiogram (echo), or by multiple gated acquisition scan (MUGA); however, patients with LVEF of between 35% and 44% may also be eligible provided that such patients are cleared by a cardiology consultation; in such cases, cardiology will determine whether it is appropriate to perform a cardiac stress test
Left ventricular ejection fraction (LVEF) > 40% (multi gated acquisition scan [MUGA] or echocardiogram) normal per institutional standard
Patients must have a left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multiple gated acquisition (MUGA) scan within 42 days prior to registration
Patients must not have presence of class III or IV heart failure, according to New York Heart Association classifications, or a known left ventricular ejection fraction of less than 50%; Note: left ventricular ejection fraction (LVEF) evaluation by echocardiogram or multi-gated acquisition scan (MUGA) is not required prior to registration
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] <40% and shortening fraction <15%). Appropriate correction to be used, if a MUGA is performed.
Abnormal left ventricular ejection fraction (LVEF; <50%) or echocardiogram ECHO or multiple gated acquisition scan (MUGA). [Applies to Phase 1 only; ECHO/MUGA scans are not performed in Phase 2.]
Left ventricular ejection fraction < 50% on echocardiogram or multi-gated acquisition (MUGA)
Left ventricular ejection fraction (LVEF) ?50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left Ventricular Shortening Fraction (LVSF) ? 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ? 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
Has a pre-study echocardiogram or multi-gated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institutional lower limit of normal within one month of initiating therapy.
Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition scan (MUGA) or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) must be equal to or greater than 50%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
Patient has a Left Ventricular Ejection Fraction (LVEF) < 50 % as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening
For participants who will be receiving CHOP: left ventricular ejection fraction (LVEF) <50% by multiple-gated acquisition (MUGA) scan or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of > 50%
Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)
Left ventricular ejection fraction less than (<) 50% as defined by multiple-gated acquisition (MUGA)
Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 55 percent (%) measured by echocardiogram (ECHO) or Multiple-Gated Acquisition (MUGA) Scan
Left ventricular ejection fraction (LVEF) >= 50% as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented =< 28 days prior to registration
Baseline left ventricular ejection fraction LVEF >= 50% as evaluated by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
Left ventricular ejection fraction (LVEF) must be equal to or greater than 40%, as measured by multi gated acquisition (MUGA) scan or echocardiogram
Patients who have abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 50%); appropriate correction to be used if a MUGA is performed
Must have an echocardiogram or multi gated acquisition scan (MUGA) indicating left ventricular ejection fraction (LVEF) >= 50% within 42 days prior to first dose of study drug
Left ventricular ejection fraction (LVEF) no more than 5 absolute percentage points below the institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration (i.e., if the institutional normal is 50%, subject's LVEF may be as low as 45% to be eligible for the study)
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scan
Baseline left ventricular ejection fraction (LVEF) >/=55% measured by echocardiogram (ECHO; preferred) or multiple-gated acquisition (MUGA) scans
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= 50% measured by multiple-gated acquisition scan (MUGA) or echocardiogram (ECHO)
Adequate cardiac function, defined as left ventricular ejection fraction ? 40% as assessed by echocardiogram or multiple uptake gated acquisition scan performed within 30 days prior to determination of eligibility
Patients must have adequate cardiac function as demonstrated by normal left ventricular ejection fraction (LVEF) >= the lower limit of normal for the facility on multi gated acquisition (MUGA) scan or echocardiogram (ECHO) within 3 months of enrollment
Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.
Left ventricular ejection fraction (LVEF) >= 50%, as determined by radionucleoventilugrams (RVG) (multi-gated acquisition-MUGA) or echocardiogram (ECHO) within 28 days prior to initiation of protocol therapy
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) greater or equal to 50% at baseline as determined by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA), or within the institution’s normal limits
Left ventricular ejection fraction (LVEF) >= 50% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)\r\n* Same method as used at baseline must be use throughout the study, ECHO is the preferred method
Left ventricular ejection fraction (LVEF) by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
Left ventricular ejection fraction >= 50%, as determined by radionuclide ventriculograms (RVG) (multi-gated acquisition scan [MUGA]) or echocardiogram within 60 days prior to initiation of protocol therapy
Left ventricular ejection fraction estimated by multi gated acquisition scan (MUGA) scan or 2-dimensional (2D)-echocardiogram of at least 45% cardiology consult is recommended prior to enrollment if a history of coronary artery disease, congestive heart failure (CHF) with estimated left ventricular ejection fraction (LVEF) of < 50% or clinically significant arrhythmia
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45% at rest (multi gated acquisition [MUGA] or echocardiogram [Echo])
Impaired cardiac function (left ventricular ejection fraction [LVEF] < 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition (MUGA) scan
For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram
Adequate cardiac function, defined by baseline LVEF greater than 50% by Multiple Gated Acquisition (MUGA) scan or echocardiogram.
Left ventricular ejection fraction assessment (echocardiogram or multiple gated acquisition [MUGA] scan) performed within 4 weeks prior to study initiation, showing a left ventricular ejection fraction (LVEF) value >= lower limit of normal (LLN)
Multiple Gated Acquisition (MUGA) or echocardiogram (ECHO) must demonstrate LVEF >/= 45%.
Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA)
Left ventricular ejection fraction measured by multi-gated acquisition scan (MUGA) or echocardiogram (ECHO) >= 45%
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gated acquisition scan [MUGA]) or echocardiogram
Subjects must have a MUGA scan or echo with LVEF >50%
Left ventricular ejection fraction (LVEF) >= 40% within 28 days prior to registration, evaluated by 2-dimensional (D) transthoracic echocardiogram (ECHO) or, if ECHO is not available, by multi-gated acquisition (MUGA) scan
History of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by echocardiogram (ECHO) or multi gated acquisition scan (MUGA); patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligible
Adequate cardiac function (left ventricular ejection fraction [LVEF] >= 40%) as assessed by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) or other similar cardiac imaging performed within 1 month of enrollment
Eligible for SCT with left ventricular ejection fraction (LVEF) >= 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO), and diffusing capacity > 50% predicted by pulmonary function testing
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) AND at least 50%; LVEF can be assessed by either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% as determined by echocardiogram or multi-gated acquisition scan (MUGA)
LVEF (left ventricular ejection fraction) of 45% or less as determined by MUGA (multi-gated acquisition) or ECHO (Echocardiogram)
Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram or multiple gated acquisition (MUGA) scan ? the lower limit of normal (LLN) for the Institution
Patients have impaired cardiac function or clinically significant cardiac diseases, including any of the following: a) history or presence of serious uncontrolled ventricular arrhythmias or presence of atrial fibrillation; b) clinically significant resting bradycardia (< 50 beats per minute); c) left ventricular ejection fraction (LVEF) assessed by 2-dimensional (D) echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) < 45%; d) pericardial effusion
Left ventricular ejection fraction (LVEF) < 45% as determined by MUGA scan or ECHO
Left ventricular ejection fraction >= 45% by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left Ventricular Ejection Fraction (LVEF) < 40% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO).
Normal left ventricular ejection fraction on screening assessed by transthoracic echocardiogram or multiple gated acquisition (MUGA) scan
Left ventricular ejection fraction (LVEF) determined by 2 dimensional echocardiogram (2D Echo) or multi-gated acquisition scan (MUGA) ? 50% or ? local institutional lower limit normal (LLN) whichever is higher.
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction as measured by echocardiogram (ECHO) or multi gated acquisition scan (MUGA) should be >= 40%
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (multi gate acquisition scan [MUGA]) or echocardiogram
Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= the lower limit of the institutional normal
Baseline multi gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 45%
LVEF <45% as determined by MUGA or echo
Baseline multiple gated acquisition (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction > 40% (multi gated acquisition scan [MUGA] or echocardiogram [echo]) within 28 days of enrollment
Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP
Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) be at least >= institutional standard of normal as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks prior to first study drug administration
Left ventricular ejection fraction >= 40% by echocardiogram (ECHO)/multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) >= 50% by MUGA (multi gated acquisition) scan or echocardiogram
Left ventricular ejection fraction (LVEF) by echocardiogram or multi gated acquisition scan (MUGA) within institutional normal limits
Subjects should have left ventricular ejection fraction (LVEF) >= 50% by echocardiogram or multi gated acquisition (MUGA) scan performed within 4 weeks prior to treatment initiation
LVEF ? 50% by MUGA or ECHO
Left ventricular ejection fraction (LVEF) results must be >= lower limit of normal (LLN) for institution performing based on results from the multi-gated acquisition (MUGA) or echocardiogram (ECHO) done at baseline
Left ventricular ejection fraction (LVEF) >= 45% by multi gated acquisition (MUGA) scan or echocardiogram
Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 4 weeks prior to registration
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) >= 50% on echocardiogram or multi-gated acquisition scan (MUGA)
Patients must have adequate cardiac function; left ventricular ejection fraction (LVEF) >= 50% as determined by multi gated acquisition (MUGA) scan or echocardiogram
Left ventricular ejection fraction >= 50% by echocardiogram (ECHO) (preferred) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction >= institutional lower limit of normal by multi-gated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
Abnormal echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) at baseline (left ventricular ejection fraction [LVEF] < 55%); appropriate correction to be used if a MUGA is performed
GROUP 2 (trametinib arm): Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
Left ventricular ejection fraction (LVEF) <50 percent (%) as measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug.